Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Tolerability of Treprostinil Administered Via a Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
NCT07923591 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Tolerability of Treprostinil Administered Via a Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
- Lead sponsor
- United Therapeutics
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- May 31, 2028
- Enrollment
- 40 (estimated)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.
pulmonary hypertension associated with chronic obstructive pulmonary disease
Arms
As registered; 2 arms.
-
treprostinil SMI
Inhaled treprostinil administered via a SMI at concentrations of 1.34, 2.68, 4.02, and 5.36 mg/mL
-
placebo
Inhaled placebo administered via a SMI
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Incidence of serious adverse events, severe adverse events, cardiopulmonary hospitalizations, and deaths
Number and type of serious adverse events, severe adverse events, cardiopulmonary hospitalizations, and deaths observed in participants during and after use of inhaled treprostinil and placebo.
Lead sponsor's other trials
United Therapeutics, most recent start first.
+79 more trials See the organization page
Similar trials
Same condition (Hypertension, Pulmonary) and phase, most recent start first.
+129 more trials See the condition page